Outcomes of Ritonavir-Boosted Protease Inhibitor Versus Non-Nucleoside Reverse Transcriptase Regimens in a Clinical Practice Cohort

Richard D Moore^1* and Ritesh Kumar²

¹Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA, E-mail: rdmoore@jhmi.edu

²Global Outcomes Research, Merck & Co., Inc., Whitehouse Station, New Jersey 08889, USA, E-mail: rdmoore@jhmi.edu

^*Corresponding Author: Richard D Moore, 1830 E. Monument St. Room 8059 Baltimore, MD 21287, USA, Fax: (410) 955-4634 Email: